Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
221
resultados
Última actualización
01/05/2026 [07:09:00]
Resultados 175 a 200 de 221
Resumen de: CN121868480A
本发明涉及生物医药技术领域，具体涉及了一种用于清除胞内细菌的纳米药物及其制备方法和用途。该纳米药物由中空介孔纳米颗粒、负载于其中的抗菌药物、接枝于颗粒表面的代谢激活分子以及包覆于最外层的经灭活细菌预刺激的免疫细胞融合膜组成。通过代谢激活、靶向杀菌、免疫唤醒的协同作用机制，有效解决了现有技术难以克服的胞内细菌代谢休眠、药物靶向递送效率低及宿主免疫抑制微环境的技术难题。实验表明，该纳米药物能特异性靶向感染部位，逆转细菌代谢休眠状态，同步实现高效杀菌与免疫激活，在对金黄色葡萄球菌等引起的胞内感染治疗中表现出卓越的清除效果，并能有效建立持久免疫记忆，显著降低感染复发率。
Resumen de: WO2025032322A1
A method of generating a plurality of different surface-decorated nanoparticles, decorated with different surface decoration, comprising: forming a plurality of microdroplets in a microfluidics device, each microdroplet comprising a nanoparticle and a respectively different macromolecule encoding a different surface decoration molecule; synthesising the surface decoration molecule, within each microdroplet, based on the macromolecule encoding the surface decoration molecule; conjugating the nanoparticle and the surface decoration molecule, within each microdroplet, to form surface decorated nanoparticles.
Resumen de: WO2025034764A1
Ionizable lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.
Resumen de: WO2025010290A1
The present disclosure relates to cationic and/or ionizable lipids and nucleic acid-lipid particle compositions comprising the same. The present disclosure also relates to methods of using and delivering the described lipids and lipid-containing particles.
Resumen de: CN121868248A
本发明公开一种光活性共轭分子的药物递送系统及其制备方法和应用，涉及光功能复合材料和生物医药技术领域。所述药物递送系统以红细胞为载体，所述红细胞的细胞内负载有光活性共轭分子和抗肿瘤药物。本发明提供的制备方法简单易行，有效整合共轭分子光敏性能与红细胞的氧气载体功能，具有良好的生物相容性和稳定性。光照后，借助红细胞的氧气运输能力，共轭分子能够在肿瘤缺氧微环境下有效地产生活性氧，同时，产生的活性氧能够破坏红细胞，实现负载药物的按需释放，达到增强光疗疗效、按需药物释放以及成像的多功能集成，实现光动力治疗与化疗的协同抗肿瘤作用。因此在生物医学领域具有很好的实用价值。
Resumen de: WO2025052296A1
The present invention belongs to the field of biomedicine and drug delivery as well as pest and vector controls. The invention relates to a novel ionizable cationic lipid family incorporating silicon, which belongs to the trademark LipexSil® second generation lipids, wherein the tail is connected to the headgroup with biodegradable silyl acetal linker. Lipids containing silyl acetal linker(s) are state-of-the-art and are effective as ionizable cationic lipids in the formulation of empty or loaded lipid nanoparticles (LNPs). The novel linkers according to the invention are designed by means of proprietary borane catalysts WO2022129966. The invention describes the synthesis of the lipids of formula (I), formation and characterization of nanoparticles and biological experiments demonstrating that the lipid nanoparticles prepared with these novel lipids can efficiently deliver their cargo (e.g. RNA, DNA, mRNA, siRNA, dsRNA, pDNA, micro RNA, circular DNA, small biologically active molecules) into the cells.
Resumen de: AU2024356988A1
Gas-filled nanobubbles for negatively charged genetic material delivery each includes a lipid membrane defining a gas containing internal void, wherein the lipid membrane includes a plurality of cationic lipids for complexing the negatively charged genetic material, an edge-activator incorporated between lipids of the membrane that enhances the flexibility of the membrane, and a membrane stiffener incorporated on an outer surface of the membrane that enhances the membrane's resistance to tearing.
Resumen de: AU2024336703A1
The present disclosure provides a pH-inducible structure-switching non-lamellar lipid nanovector (LNV) comprising: (a) at least one ionizable cationic lipid; (b) at least one phospholipid displaying a critical packing parameter (CPP) value > 1; and (c) at least one non-ionic surfactant displaying a CPP value < 1 at a molar concentration of between 20 % and 50 %, a method of making the LNV, a semi-synthetic extracellular vesicle (ssEV) resulting from the fusion of the LNV with extracellular vesicles at a pH higher than 6 and up to about 10, a kit and a use of the ssEV as a medicament or diagnostic agent.
Resumen de: AU2026202273A1
Abstract Compositions and articles comprising diamond particles, such as nanodiamond-based pharmaceutical compositions, are generally provided. In some embodiments, the articles and methods comprising (nano)diamond particles may be useful for monitoring and/or treating a disease (e.g., in a subject).
Resumen de: US20260102500A1
The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one polymethine dye and at least one polymer and/or at least one lipid and/or at least one virus-like particle, wherein the at least one polymethine dye is a symmetrical or asymmetrical polymethine.
Resumen de: US20260102348A1
An object of the present invention is to provide a compound or a salt thereof constituting lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids, and to provide lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids. According to an aspect of the present invention, a compound represented by Formula (1) or a salt thereof is provided.In the formula, X represents —NR1— or —O—, R1 represents a hydrogen atom, a hydrocarbon group, or the like, R2 and R3 each independently represent a hydrogen atom, a hydrocarbon group, or the like, R4, R5, R6, R7, R8, R9, R10, R11, and R12 each independently represent a hydrogen atom or an alkyl group, groups in any one or more pairs among R4 and R5, R10 and R5, R5 and R12, R4 and R6, R5 and R6, R6 and R7, R6 and R10, R12 and R7, and R7 and R8 may be linked to each other to form a 4- to 7-membered ring which may contain an O atom, a, b, c, and d are each independently represent an integer of 0 to 3, a+b is equal to or greater than 1, and c+d is equal to or greater than 1.
Resumen de: US20260103715A1
The invention relates to polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such polynucleotide agents to inhibit expression of PD-L1 and to treat subjects having a PD-L1-associated disorder.
Resumen de: WO2026077273A1
Provided are a composition containing a lipid nanoparticle (LNP) and an mRNA, and use thereof in the treatment of Gaucher disease. The composition contains an LNP and an mRNA, and the mRNA is encapsulated in the LNP or associated with the LNP, wherein the mRNA contains a nucleotide sequence encoding GBA1. The composition can effectively increase the expression and activity of β-glucocerebrosidase (β-GCase) in the serum and multiple target organs of a subject, and reduce the level of glucosylsphingosine (Lyso-GL1) therein. In addition, the composition possesses a relatively long half-life and has application prospects in the treatment of Gaucher disease.
Resumen de: WO2026077307A1
The present invention relates to the field of pharmaceutical technology, and in particular, to a neuroactive steroid solid dispersion, a solid dispersion composition, a method for preparing same and use thereof, and a medicament comprising the solid dispersion. The neuroactive steroid solid dispersion is obtained by melting and extruding a mixture of raw materials. In parts by mass, the mixture of raw materials comprises: 10 to 70 parts of a neuroactive steroid, 30 to 90 parts of a carrier material, and 0 to 60 parts of a plasticizer. The temperature of melting and extruding is < 160 °C. The neuroactive steroid in the neuroactive steroid solid dispersion is present in an amorphous state with a particle size of ≤ 200 nm, and features good oral bioavailability.
Resumen de: WO2024200823A1
The invention relates to a lipid-based nanoparticle comprising an antigen-binding domain capable of specifically binding to a target expressed on activated immune cells surface and one or several mRNA molecule(s) encoding an activity-enhancing protein of said activated immune cells, and to uses thereof.
Resumen de: WO2024226958A2
The present application relates a lipid, a pharmaceutical composition comprising the same, and a method of delivering an active pharmaceutical ingredient to a cell or a subject.
Resumen de: US20260102345A1
The present invention refers to polyoxyalkylene based compounds and their manufacturing method as well as compositions containing at least one polyoxyalkylene based compound and at least one active agent. Furthermore, the present invention refers to the manufacture of the compositions of the present invention as well as their use for the treatment of an illness in mammals or humans.
Resumen de: US20260102503A1
Generally, the present disclosure is directed to compositions and methods of using the same. In some embodiments, a composition described herein comprises a nanoparticle, a plurality of nanofibers disposed on an exterior surface of the nanoparticle, and a payload disposed within an interior of the nanoparticle. The nanoparticle has an average size in three dimensions, and the plurality of nanofibers has an average length in a long dimension. In some cases, a ratio of the average size of the nanoparticle to the average length of the nanofibers is between 2 and 250.
Resumen de: US20260102347A1
Provided are novel sulfur-containing lipids and nanoparticles containing such lipids and a cargo molecule, such as a nucleic acid, methods to formulate said lipids with nucleic acids to produce lipid nanoparticles and chemical routes for making said lipids. The lipids may have the structure of Formula A as defined herein. Formula A
Resumen de: US20260102357A1
The present disclosure relates to a sulfur-containing ionizable lipid or a pharmaceutically acceptable salt thereof that incorporates a dithioacetal or dithioketal moiety in one or more of its lipophilic chains. Further provided is a delivery vehicle, such as a lipid nanoparticle, comprising the ionizable lipid for the delivery of cargo, such as nucleic acid.
Resumen de: US20260102468A1
According to various aspects of this disclosure, the present disclosure relates to combination therapies, methods, and kits comprising MARCO blocking agents and anti-cancer agents for improvement of nanoformulated drug delivery. Further, wherein a method of treating a tumor or cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a combination therapy comprising a first agent and a second agent, wherein the first agent is capable of blocking the inter-action between a Macrophage Receptor with Collagenous Structure (MARCO) and a nanoparticle, and the second agent comprises an anti-cancer agent or an anti-tumor agent, and wherein at least the second agent is in the form of a nanoformulation, is disclosed.
Resumen de: US20260104425A1
The present disclosure provides a method of assessing translation efficacy of an mRNA using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The mRNA is first translated into protein either in a cell lysate (cell-free translation; CFT) or inside a cell (cell-based translation; CBT) and analyzed using LC-MS/MS. The method provides advantages such as speed and convenience over traditional immunoassay-based methods of detecting translated proteins. Translation using CBT may be necessary in certain formulations of the mRNA, such as when the mRNA or a mixture of mRNAs is encapsulated inside a lipid nanoparticle.
Resumen de: US20260102346A1
Provided is a drug delivery system, which in particular relates to a lipid composition. The shown lipid composition including a therapeutic agent and/or a prophylactic agent such as an RNA can be used for delivering the therapeutic agent and/or the prophylactic agent to a mammalian cell or organ, so as to, for example, regulate polypeptide, protein, or gene expression.
Resumen de: US20260102427A1
The invention concerns a novel and innovative composition for the treatment of neuropathic pain (NP). Specifically, the invention concerns HfO2 nanoparticles and/or aggregates of HfO2 nanoparticles, a composition comprising said nanoparticles and/or aggregates of nanoparticles, and their use in the treatment of NP.
Nº publicación: US20260103501A1 16/04/2026
Solicitante:
NUTCRACKER THERAPEUTICS INC [US]
Resumen de: US20260103501A1
Human SIRPa fusion proteins having an enhanced affinity to CD47 via increased binding valency. The human SIR-Pa fusion proteins described herein may form tetramer, hexamer, octamers, etc. These fusion proteins may be configured to form heterodimers with other fusion proteins, including C-C chemokine receptor type 4 (CCR4) binding fusion proteins.
BOPI
Sede Electrónica
